P92 C reactive protein as a predictive indicator of treatment and disease progression in patients with sarcoidosis: a retrospective observational cohort study in the West of Ireland

Abstract

patient had polyclonal hypogammaglobulinaemia, but levels were not measured in 11/42 (26%) with potential features of CVID. Conclusion Our study identified a cohort of patients with a diagnosis of sarcoidosis and features associated with CVID. We found that immunoglobulins were not being routinely measured during the work-up of patients with sarcoidosis as recommended by the Map of Medicine. Recent review of 28 local CVID patients identified two who were initially misdiagnosed with sarcoidosis. In one case this misdiagnosis persisted for 8 years. Granulomatous CVID is uncommon, but respiratory physicians should ensure that their routine work-up for sarcoidosis excludes this treatable condition.

CD4+CD31+ and CD4+CD44+ Lymphocytes in Peripheral Blood, CD8+CD31+ and CD8+CD103+ Lymphocytes in Bronchoalveolar Lavage Fluid, and Pulmonary Nodules in Predicting the Course of Pulmonary Sarcoidosis

“…None of the PFT indices at the time of manifestation of sarcoidosis was found to be a possible prognostic marker of disease course in our study. Unlike our study results, McDonnell et al in their retrospective observational study found that low DLCO at sarcoidosis presentation may identify patients without Löfgren's syndrome who are more likely to develop physiological progression [52]. However, other authors [23,53] did not confirm their findings.…”

“…Other specific potential prognostic factors found in other studies, but not confirmed or not investigated in our study are older patients' age [23,53,54], C reactive protein [52], and extrapulmonary involvement of disease [7,53].…”

“…Many clinical, biological, radiological, and PFT markers as possible predictors of the course of the disease have been studied. These include serum angiotensin-converting enzyme, C-reactive protein, immunoglobulins, soluble interleukin-2 receptor, Krebs von den Lungen-6, blood and bronchoalveolar lavage fluid (BALF) T and B lymphocytes subtypes/activation markers expression, high-resolution computed tomography (CT), fluorine-18 fluorodeoxyglucose-positron emission tomography/CT [5][6][7][8][9][10][11]. However, no reliable biological marker allows a relatively accurate assessment of the individual course of pulmonary sarcoidosis at the time of diagnosis.…”

Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis

“…In this study, ACE had a greater correlation with lung function change after methotrexate therapy than sIL-2R [73]. CRP is a proinflammatory acute phase reactant elevated in chronic sarcoidosis, and elevated baseline values may correlate with disease severity, physiologic progression of disease, and treatment response [77,78]. CRP may be useful in monitoring disease activity but requires validation.…”